Status: approved but not actively marketed

Organizations involved:

Merck & Co., Inc. – Manuf.; R&D; Tech.; World mark.

Cross ref: See the entries for component vaccines – Measles Vaccine (Attenuvax) (#491) and Rubella Vaccine (Meruvax II) (#533), both from Merck. See the Measles, Mumps and Rubella Virus Vaccine Live (M-M-R II) entry (#493). See also Measles & Rubella Virus Vaccine/GSK (#495), with the same basic components at M-R-Vax II.

Description: Measles and Rubella Virus Vaccine Live or M-R-Vax II is a bivalent combination vaccine formulated from Measles Vaccine (Attenuvax) and Rubella Vaccine (Meruvax II), both from Merck & Co., Inc.

Nomenclature: Measles & Rubella Virus Vaccine/Merck [BIO]; -M-R-Vax II [TR]; Measles and Rubella Virus Vaccine Live [FDA]; Measles and Rubella Virus Vaccine, Live [FDA former]

History: Dow Chemical Co. (est. no. 0110) was licensed to manufacture Measles and Rubella Virus Vaccine, Live from April 1974-June 1978.

Companies.: M-R-Vax II was developed and is manufactured by Merck & Co., Inc. (West Point, PA), FDA CBER est. no. 0002. It is marketed in the U.S. by Merck & Co., and internationally by Merck affiliates.

FDA class: Biologic PLA

CBER class: Viral And Rickettsial Vaccines

Approvals: Date = 19710422; first approval, PLA

Date = 19860106, product license revoked and granted (reissued) under new (current) FDA proper name

Indications: prevention of disease due to measles and rubella virus infection [unofficial]

Market: Average Wholesale Price (AWP) not available (product not in 2007, 2005 or 2004 Red Book), indicating the product is not actively marketed in the U.S.

Nearly all children receiving vaccination for mumps and measles now receive the combination measles, mumps, and rubella vaccine (M-M-R II) or newer ProQuad.